Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Should Basilea Pharmaceutica Be Trading At Twice This Price?

The biotech sector has fallen on hard times, with momentum investors fleeing the space and those who remain taking a much more careful look at just how much they are willing to pay for these speculative stocks. Caught up in the mix is the very under-covered Basilea Pharmaceutica (OTC:BPMUF), a small-cap Swiss biotech focused on antibiotics, antifugals, and oncology drugs. While the company does not yet have a drug approved in the U.S., key filings are close at hand for multiple drugs.

Investors should note that Basilea's U.S. ADRs are very illiquid. With less than 10 million shares outstanding, an average volume of about 110,000, and three analysts covering the company it is not as though the Swiss-listed...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details